Ownership Summary
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) currently has 9 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).
- Sensei Biotherapeutics saw its institutional ownership percentage fell to 2.1% in December 2025 from 3.9% in September 2025.
- On a quarter-over-quarter basis, institutional holdings shifted by 3.59%, with a year-over-year a decrease of 64.00% in the count of filers.
- The latest 13F cycle for Sensei Biotherapeutics reveals that of 9 total investors, 3 funds grew their exposure, whereas 2 reduced theirs and 4 made no changes.
- This class of investors increased its holdings in Sensei Biotherapeutics to 26.90K shares for the 13F-cycle ending December 2025, up by 931 shares quarter on quarter, and down 2.34Mn shares year over year.
- The top institutional stake in Sensei Biotherapeutics as of December 31, 2025 belongs to Catalio Capital Management, LP, which owns 14.72K shares, or 1.17% of the company.
- Among the most significant buyers of Sensei Biotherapeutics during December 2025 were RENAISSANCE TECHNOLOGIES LLC (1.10K), CITIGROUP INC (294), BNP PARIBAS (7).
- Leading sellers of Sensei Biotherapeutics stock in December 2025 included BANK OF AMERICA CORP /DE/ (325), SBI Securities Co., Ltd. (145).
- The top 9 institutional holders of Sensei Biotherapeutics for the quarter ending December 2025 included Catalio Capital Management, LP (14.72K), RENAISSANCE TECHNOLOGIES LLC (11.52K), BANK OF AMERICA CORP /DE/ (306), CITIGROUP INC (294), JPMORGAN CHASE & CO (32), MORGAN STANLEY (10), BNP PARIBAS FINANCIAL MARKETS (9), BNP PARIBAS (7), SBI Securities Co., Ltd. (4).